Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IlluminaXSWX:ILMN 76 Revenue per Share is CHF23.27 as of Jun. 2026. GuruFocus rates XSWX:ILMN with a GF Score™ of 76/100 and a GF Value™ of CHF107.32. The stock has 7 warning signs investors should review. Among 192 Medical Diagnostics & Research companies, Illumina ranks worse than 55.21% on this metric.
Illumina's revenue per share for the
three
months ended in Jun. 2026 was CHF6.06.
Illumina's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was CHF23.27.
Warning Sign:
Illumina Inc revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Illumina was 8.50% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -1.60% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 2.70% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 6.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Illumina's Revenue per Share or its related term are showing as below:
XSWX:ILMN'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -2.8 Med: 17.65 Max: 156.2
Current: -1.6
During the past 13 years, Illumina's highest 3-Year average Revenue Per Share Growth Rate was 156.20% per year. The lowest was -2.80% per year. And the median was 17.65% per year.
XSWX:ILMN's 3-Year Revenue Growth Rate is ranked worse than 55.21% of 192
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.35
vs XSWX:ILMN: -1.60
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Illumina Revenue per Share Related Terms
Illumina Revenue per Share Historical Data
* Premium members only.
The historical data trend for Illumina's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ILMN vs MTD, DGX, LH: Revenue per Share Comparison
For the Diagnostics & Research subindustry, Illumina's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's PS Ratio distribution charts can be found below:
* The bar in red indicates where Illumina's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Illumina's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF23.27
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Illumina (XSWX:ILMN) has a Revenue per Share of CHF23.27 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Illumina and its competitors. According to the industry distribution chart, Illumina ranks #106 out of 192 companies in the Medical Diagnostics & Research industry, placing it in the top 55.2%.
Is Illumina's Revenue per Share too high?
Illumina's current Revenue per Share is CHF23.27. Based on the distribution chart, Illumina ranks #106 out of 192 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Illumina has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Illumina's Revenue per Share compare to MTD and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Illumina ranks #106 out of 192 companies for Revenue per Share. This places Illumina in the lower half of its industry. The industry median Revenue per Share is 1.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Diagnostics & Research company?
The median Revenue per Share among Medical Diagnostics & Research companies is 1.35, based on 192 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Illumina and its competitors. For the Medical Diagnostics & Research industry, the median Revenue per Share is 1.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Illumina's current Revenue per Share is CHF23.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Illumina (XSWX:ILMN) has a current Revenue per Share of CHF23.27. The stock's GF Value™ is CHF107.32, compared to a current price of CHF155.14 — trading 44.6% above its estimated fair value. The current Revenue per Share is CHF23.27. Illumina's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Illumina (XSWX:ILMN), the current Revenue per Share is CHF23.27 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Illumina (XSWX:ILMN) Overvalued in 2026?
Based on GuruFocus' analysis, Illumina stock appears to be overvalued.
The current stock price of CHF155.14 is trading 44.6% above its estimated GF Value™ of CHF107.32.
Key valuation signals for XSWX:ILMN:
Revenue per Share: CHF23.27
GF Value™: CHF107.32 vs. price of CHF155.14 (44.6% above fair value)
No single metric tells the full story. See the XSWX:ILMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
76GF Score
Get the complete analysis for XSWX:ILMN
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ILMN has been successfully added to your 
